Navigation Links
Veteran-Owned Biotech Startup Company Charges Health Agency (NYSDOH) with Blackballing its Initiatives
Date:5/12/2009

NEW YORK, May 12 /PRNewswire/ -- A U.S. company registered by the Department of Veterans Affairs and the Center for Veterans Enterprise as a veteran-run business filed complaints with the U.S. Department of Veterans Affairs, and with NYS Governor David A. Paterson, alleging discriminatory practices by the New York State Department of Health (NYSDOH).

"Fortunately, the VA has programs for the support of veteran-owned enterprises, and I am grateful for them," said Gerard Sunnen, MD, president of Ozonics International, a startup company engaged in the research and development of proprietary biotechnologies, adding, "the DOH, known for its hyperconservatism, has long had an adversarial relationship with complementary medicine research and practice; but here, there is such an extreme pattern that the very success of Ozonics is in the balance." Dr. Sunnen reports that the DOH abuses its power by freely dispensing information that is false and clearly defamatory to Ozonics, thus severely compromising its commercial initiatives.

Information about the DOH's actions is found in press and Internet releases entitled "New York State Department of Health (NYSDOH) stops a world-first U.S.-Egyptian collaborative study on hepatitis C and blood ozonation." This contracted study aimed to investigate the stimulating effects on the immune system of minuscule doses of ozone administered to blood, as reported by researchers in Italy, Germany, Russia, and Japan. Such immune enhancement is said to lead to viral load reduction and to the normalization of liver enzyme levels. Dr. Sunnen added, "This study carried special significance for Egypt which is overwhelmed with the highest prevalence of hepatitis C in the world. Furthermore, the fruits of this landmark research would have immediately transferred to hepatitis C sufferers in the U.S., including the one million or so veterans so afflicted."

Another press release, "Breakthrough ozone-based medical technologies facing challenges from Department of Health (NYSDOH)," reports on impediments to research initiatives in the spectrum of potential clinical applications for ozone. Based on ozone gas' remarkable antimicrobial properties, for example, topical oxygen/ozone mixtures have documented applications in the treatment of diabetic and pressure skin ulcers, and all manner of infected lesions, including war wounds.

"The derailment of the Egyptian hepatitis C study by the NYSDOH," Dr. Sunnen continued, "was an affront to medical collaboration in the Middle East, which continues to have unfortunate repercussions. Additionally, research thrusts aimed at diabetic skin ulcers have met unusual resistance. And, recently, Ozonics experienced a setback in a U.S.- Australian endeavor using Ozonics' proprietary technology integrating microwave and ultraviolet energy, and ozone, for rapidly disinfecting large spaces such as airport terminals and hospital facilities, with special reference to airborne viruses, such as influenza, in the context of epidemic situations."

Ozonics is petitioning the Veterans Administration and NYS Governor David A. Paterson for a cease and desist directive relative to the NYSDOH's blackballing of Ozonics' operations. "Amazingly, a state agency - in this case the NYSDOH - is not only given power to impose its proprietary brand of laws, but is also given carte blanche for nixing legitimate medical research." Dr. Sunnen added, "Whatever agendas are at play, such counterproductive actions only smother promising clinical initiatives, and ultimately rob patients of their hopes and their right to medical innovations."

    For more information, contact:
    Gerard Sunnen, M.D.
    President, Ozonics International, LLC
    200 E. 33 St.
    New York, NY 10016
    Email: Ozonicsint@aol.com


'/>"/>
SOURCE Ozonics International, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 05, 2016 , ... This composition patent, U.S. Patent No. ... The composition claims are not limited to any particular process to make or ... carbon fibers, graphene, and other materials. A continuation application, U.S. Patent App. ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, announced ... the company as Chief Financial Officer (CFO), effective ... with 20 years of experience in financial management ... biotech and software companies. Most recently, Ms. Bovenizer ...
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... ... ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility in ... Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will meet ... to discuss the benefits of a viscoelastic disc. AxioMed received CE mark in ...
Breaking Biology Technology:
(Date:11/30/2016)... SAN FRANCISCO and WARSAW, Poland , Nov. 30, 2016 ... sleeping. It is one of the most crucial aspects of recovery so we need ... host of serious health risks, including heart problems, high blood pressure, stroke, diabetes, and ... family and friends sleep and find a Christmas present that could help them to ... ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
Breaking Biology News(10 mins):